Donald Trump: What medtech’s top executives are saying

February 3, 2017 By Chris Newmarker

Baxter CEO Jose Almeida [Image courtesy of Baxter]

Baxter CEO Joe Almeida [Image courtesy of Baxter]

“Listen, it’s very uncertain right now with this whole review and replace [of ACA], what would be actually the replacement policy and what is going to be in place to bring coverage to people that maybe out of coverage. So, I think hospitals always take a pause at big capital items and investment in expansion. I would say that the capital plans that we have — the capital products that we have, rather, are small capital investments that the hospital needs to make. Those are pumps, they need the pumps; these are not big diagnostic machines. So, I would say that if there is effect and it’s a cascading effect, we’re probably at the tail end of it and we’re still little of that if any into 2017.” —Baxter CEO Joe Almeida, Feb. 1

Next>>

Pages: 1 2 3 4 5 6 7 8

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.